Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-cash Items (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Non-cash Items for 3 consecutive years, with $412000.0 as the latest value for Q4 2025.

  • For Q4 2025, Non-cash Items fell 94.21% year-over-year to $412000.0; the TTM value through Dec 2025 reached $412000.0, down 94.21%, while the annual FY2025 figure was $412000.0, 94.21% down from the prior year.
  • Non-cash Items hit $412000.0 in Q4 2025 for Artiva Biotherapeutics, up from $180000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $7.1 million in Q4 2024 and bottomed at $180000.0 in Q3 2025.
  • Average Non-cash Items over 3 years is $1.6 million, with a median of $1.1 million recorded in 2024.
  • Year-over-year, Non-cash Items surged 3226.17% in 2024 and then crashed 94.21% in 2025.
  • Artiva Biotherapeutics' Non-cash Items stood at $214000.0 in 2023, then soared by 3226.17% to $7.1 million in 2024, then plummeted by 94.21% to $412000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $412000.0, $180000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.